UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	s)												
Name and Address of Reporting Person* LOBELL J JAY			2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X_ Director 10% Owner					
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 2 GANSEVOORT STREET, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 01/01/2019					-	Office	r (give title belo	ow)	Other (specify b	elow)
(Street) NEW YORK, NY 10014			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		Transaction ite Ionth/Day/Year)	2A. Deemed Execution Date, any	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D)	D) Beneficially Owned Follow Reported Transaction(s)		Following	Ownership Form:	7. Nature of Indirect Beneficial
			(Month/Day/Yea	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)			\ /	Ownership (Instr. 4)
Common Stock	01	/01/2019		A		100,000	A	\$ 0	936,000			D	
Reminder: Report on a s	separate line for ea	ach class of secur	rities beneficially	owned dire	Pers	ons who				ction of inf			1474 (9-02)
Reminder: Report on a	separate line for ea	Table II - 1	Derivative Secur	ities Acqui	Pers cont the f	sons who tained in t form disp	this for lays a	m are curren eficiall	not requ tly valid	uired to res	ormation spond unle trol numbe	ss	1474 (9-02)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security	3. Transaction Date	Table II - 1 (3A. Deemed Execution Da any		ities Acquivarrants, (Pers cont the f	sons who tained in t form disp	this for lays a control or Bendelsecur sable Date	eficiallrities) 7. Tit Amo Under	not requitly valid y Owned the and unt of erlying	OMB conf	spond unle	of 10. Ownersl Form of Derivati Security Direct (1 or Indire	11. Natu of Indire Benefici: Ownersh (Instr. 4)

Reporting Owners

	Relationships			
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
LOBELL J JAY C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X			

Signatures

/s/ Samuel Berry / Attorney-in Fact	04/12/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) One-third of the shares will vest on each of January 1, 2020, 2021 and 2022, subject to continued service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.